ReviewNature reviews. Cardiology2014
PET imaging of inflammation in atherosclerosis.
Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 2 syntheses or guidelines pooled it, 377 citations in OpenAlex.
- Discussion on the comparison of Raman spectroscopy and cardiovascular disease-related imaging techniques and the future applications of Raman technology: a systematic review.Lasers in medical science · 2025Pooled it
- Automated Coronary Optical Coherence Tomography Feature Extraction with Application to Three-Dimensional Reconstruction.Tomography (Ann Arbor, Mich.) · 2022Pooled it
- Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial.Nature medicine · 2026Trial
- Detection of Atherosclerotic Inflammation byJournal of the American College of Cardiology · 2017 · on this mapTrial
- Thoracic aorta calcification but not inflammation is associated with increased cardiovascular disease risk: results of the CAMONA study.European journal of nuclear medicine and molecular imaging · 2017Trial
- Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.Circulation · 2016Trial
- PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracerEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Delayed total-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Targeting Inflammation Across the Myocardial Infarction Continuum: Biomarkers, Imaging, and Emerging Therapies.Journal of clinical medicine · 2026Review
- Pathological depositions in human disease: converging mechanisms in atherosclerosis, Alzheimer's disease, and related disorders.Molecular biomedicine · 2026Review
- Next-Generation Cardiovascular Imaging in Precision Medicine: Integrating Functional Imaging, Artificial Intelligence, Biomarkers, and Personalized Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Review
- Heterogeneity of vascular inflammation in obstructive sleep apnea: effects of continuous positive airway pressure therapy.Annals of the American Thoracic Society · 2026Article
- [EJNMMI research · 2026Article
- Article
- Integration of Conventional and Radiomic Features From Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging for Multimodal Prediction of Symptomatic Carotid Atherosclerotic Plaques.Journal of the American Heart Association · 2026Article
- Cholesterol-Inflammation Fusion Hypothesis in Atherosclerosis: An Evolving Paradigm in Pathogenesis and Therapy.JACC. Asia · 2026Review
- Ninjurin1 in cardiovascular and vascular biology: From molecular mechanisms to therapeutic opportunities.Clinical and translational medicine · 2026Review
- Optimizing PET/CT protocols: is 60-minute [18 F]F-FDG uptake sufficient for cardiac sarcoidosis?EJNMMI research · 2026Article
- Mapping the immune environment: spatiotemporal dynamics in cardiovascular events.Frontiers in immunology · 2026Review
- Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
PET imaging of atherosclerosis can quantify several in vivo pathological processes occurring within the arterial system. (18)F-fluorodeoxyglucose (FDG) is the most-commonly used PET tracer, with well-established roles in atherosclerosis imaging. In this context, the (18)F-FDG signal largely reflects tracer uptake by plaque macrophages and, therefore, inflammation with smaller contributions from other resident cell types. As a marker of plaque vulnerability, the (18)F-FDG PET signal can be used to help to identify patients at the highest risk of clinical events. (18)F-FDG PET has also been used successfully as a surrogate end point in clinical trials of antiatherosclerotic therapies. Nonetheless, imaging atherosclerosis with (18)F-FDG has several limitations. Most importantly, coronary artery imaging is problematic because (18)F-FDG accumulates in all cells that metabolize glucose, and background myocardial uptake is generally greater than any signal originating from a plaque. To help to overcome these limitations, several novel PET tracers, which might be more-specifically targeted than (18)F-FDG, have been tested in atherosclerosis imaging. These tracers are designed to track inflammation, hypoxia, neoangiogenesis, or active calcification, which are all precursors to plaque rupture and its clinical sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.